Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Recruiting 2Not yet recruiting 2

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Lung Neoplasms 53Leukemia, Myeloid, Acute 52Neoplasm Metastasis 45Carcinoma, Non-Small-Cell Lung 40Prostatic Neoplasms 37Breast Neoplasms 36Multiple Myeloma 31Colorectal Neoplasms 29Pancreatic Neoplasms 26Carcinoma, Renal Cell 25Melanoma 23Ovarian Neoplasms 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 20Lymphoma 20Leukemia, Lymphocytic, Chronic, B-Cell 20Burkitt Lymphoma 19Lymphoma, Large B-Cell, Diffuse 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Urinary Bladder Neoplasms 16Carcinoma, Hepatocellular 16Squamous Cell Carcinoma of Head and Neck 15Glioblastoma 15Fallopian Tube Neoplasms 14Oropharyngeal Neoplasms 13Glioma 13Endometrial Neoplasms 13Sarcoma 12Mouth Neoplasms 12Lymphoma, Non-Hodgkin 12

Interventions

Fluorouracil 14Nivolumab 13Oxaliplatin 12Leucovorin 11Paclitaxel 7Capecitabine 7pembrolizumab 6Radiotherapy 5Cisplatin 5Taxes 4Specimen Handling 4Radiation 4Irinotecan 4Drug Therapy 4dehydroftorafur 3Trastuzumab 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2futibatinib 2Levoleucovorin 2Endoscopy, Digestive System 2Endoscopy 2Carboplatin 2Biopsy 2zolbetuximab 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Specimen Handling × 90 days × Clear all
NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04939051 2026-05-13

Obeticholic Acid for Prevention in Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT06732388 2026-05-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
64 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡